



Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors

London, UK, June 16, 2014 – Avillion LLP, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development to marketing approval, is pleased to announce that Ulf Wiinberg has been elected as Chairman of its Board of Directors.

Mr Wiinberg is Chief Executive Officer (CEO) of H. Lundbeck A/S, a position he has held since June 2008. Before joining Lundbeck, he worked at Wyeth/Lederle for 27 years, most recently as President of Wyeth Europe and Wyeth BioPharma. He is presently a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturer Association (IFPMA), Pharmaceutical Research and Manufacturers of America (PhRMA). In Denmark, Mr Wiinberg serves on the Industrial Policy Committee under the Confederation of Danish Industry, and he is a member of the board of directors of Alfa Laval, a large Public Company in Sweden.



Genghis Lloyd-Harris, a non-executive director of Avillion and a Partner at Abingworth LLP, said: “On behalf of the Board of Directors, I am pleased to welcome Ulf as Avillion’s Chairman. His election represents another significant step for Avillion. Ulf’s knowledge and experience will be highly valuable as the company executes its innovative strategy and expands its profile as a late-stage drug development partner of choice.”

Ulf Wiinberg added: “Avillion is making great progress in addressing an important area of late-stage drug development; by leveraging its experienced clinical development team and financial resources, Avillion enables pharmaceutical partners to continue to advance their most important drug candidates while managing their internal resource limitations. I am delighted to join the Company as Chairman and look forward to supporting its further growth and development.”

ENDS

About Avillion

Avillion LLP is a drug development company with an innovative business model focusing on the clinical development and regulatory approval of late stage pharmaceutical products. Avillion LLP offers a compelling opportunity to partner late-stage therapeutic projects for approval in the US and EU and to accelerate their availability to the market. Our objective is to enable our partners to continue to develop the drug candidates in their pipeline without increasing the burden on their P&L or cash reserves. Avillion LLP can achieve this by incurring 100% of the clinical and regulatory risk, while advancing the development of these late-stage assets.

Avillion was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma. www.avillionllp.com

Contacts

Allison Jaynes-Ellis, CEO
Tel: +44 (0)207 470 2458
Email: allison@avillionllp.com

Mark Swallow, Citigate Dewe Rogerson
Tel: +44 (0)207 282 2948
Email: mark.swallow@citigatedr.co.uk

AVILLION